
Compass Therapeutics (CMPX) Stock Forecast & Price Target
Compass Therapeutics (CMPX) Analyst Ratings
Bulls say
Compass Therapeutics is supported by a differentiated bispecific antibody platform with multiple shots on goal, led by tovecimig’s positive COMPANION-002 readout showing 18% ORR versus 5.3% and median PFS of 4.7 months versus 2.6 months, alongside no new safety signals. The outlook remains constructive because the company has $179.9MM in cash to fund development, is advancing CTX-8371, CTX-10726, and CTX-471, and has key data expected in 4Q26, reducing near-term financing pressure while preserving pipeline optionality. Although the FDA requested an additional survival trial in 2L+ BTC, the company’s continued dialogue is viewed as the most prudent path in a setting of significant unmet need and a large potential market opportunity.
Bears say
Compass Therapeutics is facing a fundamentally difficult regulatory path because the FDA has recommended an additional survival-benefit trial before a tovecimig BLA, while the company has no confirmatory study enrolling and cannot yet resolve the agency’s concerns through meetings or further clarification. Although COMPANION-002 showed meaningful activity with ORR of 18.0% versus 5.3% and mPFS of 4.7 versus 2.6 months, overall survival was not statistically significant and the crossover-adjusted OS signal remains weak, leaving the approval case dependent on an argument regulators have already questioned. Financially, the company reported a Q3 net loss of $27.2 million, had $163 million in cash, and expects runway into 2028, but the valuation remains pressured by regulatory uncertainty and the risk that pipeline progress does not translate into revenue.
This aggregate rating is based on analysts' research of Compass Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Compass Therapeutics (CMPX) Analyst Forecast & Price Prediction
Start investing in Compass Therapeutics (CMPX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Compass Therapeutics (CMPX) Forecast
Compass Therapeutics (CMPX) Analyst Forecast & Price Prediction
Start investing in Compass Therapeutics (CMPX)
Order type
Buy in
Order amount
Est. shares
0 shares